The Curious Case of Lifespot, page-15

Best case proposition for LSH might look like:

Success with the trial run of 500 vaping units to Ionic (just getting the order and payment for the units was a good achievement) leading to additional larger orders. Sparks interest from other potential partners and we see another distributor in (say) Canada formalise a partnership with LSH to sell the vape units. If a second and/or third distribution deal was signed, as well as orders placed for supply it would really put a rocket under
the SP.

Payments from these partners might help LSH avoid an excessive CR. I doubt they could avoid it completely but it’s possible.

Something (anything) happens with Bodytel products, leading to revenues but I’m not optimistic about that as another member correctly pointed out - these have been on the market with B. Braun (and possibly a second seller I can’t recall) in Germany for quite some time and have simply died. It’s possible Bodytel can be tweaked and adapted to meet the needs of some different health conditions but the current tool seems dead in the water.

Upside here (based mainly on the vape and avoiding excessive CR) would have to be a market cap of ballpark $20m-$30m or a share price of around 60c. Again, not a prediction but it’s all possible.